In hTERT-RPE1 cells, 1 μM GSK2636771 partially inhibited serum- and LPA-induced primary cilia disassembly after 1 h pretreatment and 24 h stimulation with inhibitor present. The study explicitly identifies Adooq A11784. The partial response supports a contribution of PI3Kβ within a broader cilia disassembly network. [2]
GBM cell responses varied with the model. After 4 days, GSK2636771 MTS viability IC50 values were 14.8 μM in U87MG and 15.7 μM in SF-295, versus reported fitted values of 140.6 μM in A172 and 62.7 μM in LN229. The latter estimates exceed the displayed dose range through 25 μM. [3]
PI3K isoform enzyme inhibition
Biochemical assay · Human PI3K isoform biochemical activity assays [1]
GSK2636771 inhibited PI3Kβ more potently than PI3Kα, PI3Kδ or PI3Kγ. Enzyme IC50 values and SD are distinct from the kinobead binding values in the adjacent column.
Literature-Reported Treatment Conditions
- Method
- PI3-Kinase HTRF assay (EMD Millipore); comparison across human PI3K isoforms
- Reported limits
- Assay concentrations, ATP concentration, incubation duration and replicate n are not specified in the reviewed assay description. No treatment dose inferred from IC50.
Methods and source locations
Compound reported in the paper: GSK2636771
Evidence concerns the material tested in this paper; it does not validate a current catalog lot or an alternative salt/form.
Accepted manuscript pp. 7–8; Fig. 1A–B on p. 36 and caption p. 33
Human PI3Kβ enzyme inhibition: Biochemical activity assay; mean IC50 ± SD column; replicate n not stated. — Fig. 1B enzyme assay column, accepted manuscript p. 36; selectivity methods p. 8
Human PI3Kα enzyme inhibition: Biochemical activity assay; mean IC50 ± SD column; replicate n not stated. — Fig. 1B enzyme assay column, accepted manuscript p. 36; selectivity methods p. 8
Human PI3Kδ enzyme inhibition: Biochemical activity assay; mean IC50 ± SD column; replicate n not stated. — Fig. 1B enzyme assay column, accepted manuscript p. 36; selectivity methods p. 8
Human PI3Kγ enzyme inhibition: Biochemical activity assay; mean IC50 ± SD column; replicate n not stated. — Fig. 1B enzyme assay column, accepted manuscript p. 36; selectivity methods p. 8
Partial inhibition of induced cilia disassembly
Cell-based study · Parental human hTERT-RPE1 retinal pigment epithelial cells [2]
GSK2636771 partially impaired serum- and LPA-induced cilia disassembly compared with DMSO. This is a cellular phenotype supporting a contribution of PI3Kβ, rather than proof that PI3Kβ alone controls disassembly.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 μM
- Exposure duration
- 1 h pretreatment followed by 24 h stimulation with inhibitor present; prior serum starvation 48 h
- Method
- Cilia scoring after serum or 2 μM LPA stimulation
- Vehicle
- DMSO
- Co-treatment
- Serum or LPA are disassembly stimuli, not a second inhibitor.
- Reported limits
- Final DMSO percentage not specified in the selected assay description. Exact ciliated-cell means are not extracted from bars.
Methods and source locations
Compound reported in the paper: GSK2636771
Evidence concerns the material tested in this paper; it does not validate a current catalog lot or an alternative salt/form.
Results Par21–Par22; Fig. 3f; Methods, Cell culture, cilia assembly/disassembly assay paragraph
Percentage of ciliated cells after induced disassembly: Fig. 3f; one-way ANOVA with Tukey post hoc per Statistics & reproducibility. Overall ANOVA p = 1.06 × 10−6 (serum), p = 0.0043 (LPA); these are not GSK-versus-DMSO pairwise p-values. — Fig. 3f image and caption; Results Par22; Methods, Statistics & reproducibility
Model-dependent GBM cell viability response
Cell-based study · U87MG, SF-295, A172 and LN229 human GBM cell lines [3]
GSK2636771 suppressed viability more strongly in p110β-high U87MG and SF-295 than in p110β-low A172 and LN229 cells. Reported fitted IC50 values for the low-response lines exceed the displayed concentration range.
Literature-Reported Treatment Conditions
- Treatment concentration
- Displayed dose-response series through 25 μM; no IC50 value treated as an administered concentration
- Exposure duration
- 4 days
- Method
- MTS viability assay; IC50 calculated using GraphPad Prism
- Vehicle
- DMSO; final percentage not specified
- Reported limits
- Independent replicate n and figure-specific MTS error-bar definition are not specified in the Fig. 5 caption. Values exceeding 25 μM are fitted estimates beyond the displayed range.
Methods and source locations
Compound reported in the paper: GSK2636771
Evidence concerns the material tested in this paper; it does not validate a current catalog lot or an alternative salt/form.
Fig. 5A and caption; Methods, Cell Viability and Growth; Results, PI3K Isoform-Selective Inhibitors as a New Treatment for GBM
U87MG cell viability: MTS assay after 4 days; figure-printed fitted IC50, not an enzyme potency. A172 and LN229 values exceed the displayed tested range. — Fig. 5A printed IC50 table; Methods, Cell Viability and Growth
SF-295 cell viability: MTS assay after 4 days; figure-printed fitted IC50, not an enzyme potency. A172 and LN229 values exceed the displayed tested range. — Fig. 5A printed IC50 table; Methods, Cell Viability and Growth
A172 cell viability: MTS assay after 4 days; figure-printed fitted IC50, not an enzyme potency. A172 and LN229 values exceed the displayed tested range. — Fig. 5A printed IC50 table; Methods, Cell Viability and Growth
LN229 cell viability: MTS assay after 4 days; figure-printed fitted IC50, not an enzyme potency. A172 and LN229 values exceed the displayed tested range. — Fig. 5A printed IC50 table; Methods, Cell Viability and Growth